Intravenous Artesunate for Severe Malaria in Travelers, Europe

Zoller, Thomas; Junghanss, Thomas; Kapaun, Annette; Gjørup, Ida; Richter, Joachim; Hugo-Persson, Mats; Mørch, Kristine; Foroutan, Behruz; Suttorp, Norbert; Yürek, Salih; Flick, Holger

doi:10.3201/eid1705.101229

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Intravenous Artesunate for Severe Malaria in Travelers, Europe

Published Date:

May 2011

Publisher's site:

http://dx.doi.org/10.3201/eid1705.101229 New Site Icon

Source:

Emerg Infect Dis. 17(5):771-777.

[PDF-293.83 KB]

Details:

Alternative Title:

Emerg Infect Dis

Personal Author:

Zoller, Thomas ; Junghanss, Thomas ; Kapaun, Annette ; Gjørup, Ida ; Richter, Joachim ; ... More ▼

Description:

Multicenter trials in Southeast Asia have shown better survival rates among patients with severe malaria, particularly those with high parasitemia levels, treated with intravenous (IV) artesunate than among those treated with quinine. In Europe, quinine is still the primary treatment for severe malaria. We conducted a retrospective analysis for 25 travelers with severe malaria who returned from malaria-endemic regions and were treated at 7 centers in Europe. All patients survived. Treatment with IV artesunate rapidly reduced parasitemia levels. In 6 patients at 5 treatment centers, a self-limiting episode of unexplained hemolysis occurred after reduction of parasitemia levels. Five patients required a blood transfusion. Patients with posttreatment hemolysis had received higher doses of IV artesunate than patients without hemolysis. IV artesunate was an effective alternative to quinine for treatment of malaria patients in Europe. Patients should be monitored for signs of hemolysis, especially after parasitologic cure.

Subject:

[+]

Document Type:

Journal Article

Collection(s):

Emerging Infectious Diseases

Main Document Checksum:

[+]

Supporting Files:

	10-1229-F.gif	image/gif
	10-1229-F.jpg	image/jpeg
	10-1229_finalS.nxml	text/plain
	license.txt	text/plain

No Related Documents.

You May Also Like:

Published Reports of Delayed Hemolytic Anemia After Treatment with Artesunate for Severe Malaria — Worldwide, 2010–2012

Personal Author:

Briggs, Melissa; Arguin, Paul M.;

Published Date:

Jan 11 2013

Source:

MMWR Morb Mortal Wkly Rep. 2013; 62(1):5-8.

Description:

Artesunate has been recommended by the World Health Organization (WHO) as the first-line treatment for severe malaria since 2010. It is not licensed in the United States but is available from CDC under an investigational new drug (IND) protocol. Duri...

File Type:

[PDF - 190.15 KB]
Severe Malaria and Artesunate Treatment, Norway

Personal Author:

Mørch, Kristine; Strand, Øystein; Dunlop, Oona; Berg, Åse; Langeland, Nina; Leiva, Rafael A.M.; Longva, Jørn-Åge; Sjursen, Håkon; Skrede, Steinar; Sundal, Jon; Jensenius, Mogens;

Published Date:

Nov 2008

Source:

Emerg Infect Dis. 14(11):1816-1818

File Type:

[PDF - 185.38 KB]
Delayed-Onset Hemolytic Anemia in Patients with Travel-Associated Severe Malaria Treated with Artesunate, France, 2011–2013

Personal Author:

Jauréguiberry, Stéphane; Thellier, Marc; Ndour, Papa Alioune; Ader, Flavie; Roussel, Camille; Sonneville, Romain; Mayaux, Julien; Matheron, Sophie; Angoulvant, Adela; Wyplosz, Benjamin; Rapp, Christophe; Pistone, Thierry; Lebrun-Vignes, Bénédicte; Kendjo, Eric; Danis, Martin; Houzé, Sandrine; Bricaire, François; Mazier, Dominique; Buffet, Pierre; Caumes, Eric;

Corporate Authors:

French Artesunate Working Group

Published Date:

May 2015

Source:

Emerg Infect Dis. 21(5):804-812.

Description:

Artesunate is the most effective treatment for severe malaria. However, delayed-onset hemolytic anemia has been observed in ≈20% of travelers who receive artesunate, ≈60% of whom require transfusion. This finding could discourage physicians from ...

File Type:

[PDF - 1.26 MB]
MMWR. Morbidity and mortality weekly report, Vol. 62, no. 1, January 11, 2013

Corporate Authors:

Centers for Disease Control and Prevention (U.S.)

Published Date:

January 11, 2013

Series:

MMWR. Morbidity and mortality weekly report ; v. 62, no. 1

File Type:

[PDF - 453.00 KB]
Severe Delayed Hemolysis Associated with Regulated Parenteral Antimalarial Drug

Personal Author:

Lee, Julia; Krajden, Sigmund; Graham, Christopher; Boggild, Andrea K.; Pavenski, Katerina; Keystone, Jay S.; Kain, Kevin C.;

Published Date:

2015

Source:

Emerg Infect Dis. 21(1):164-166.

File Type:

[PDF - 285.54 KB]